EUCTR2010-023909-35-FR进行中（未招募）1 期
A Prospective, Randomized, Double-Blind, Phase 3 Study Comparing rhBSSL and Placebo Added to Infant Formula or Pasteurized Breast Milk During 4 Weeks of Treatment in Preterm Infants Born Before Week 32 of Gestational Age - BVT.BSSL-030
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 432
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Preterm infant born before Week 32 of gestation.
- •2. Preterm infant who is <33 weeks postmenstrual age at the time of randomization.
- •3. Preterm infant who is AGA or SGA at birth.
- •4. Preterm infant who is receiving food enterally (bottle or gavage tube) at a level of at least 100 mL/kg/day at randomization.
- •5. Preterm infant whose enteral feeding consists of only infant formula or only PBM at the time of inclusion, and who are expected to remain on only infant formula for 4 weeks, or only PBM for at least 2 weeks following treatment initiation.
- •6. Preterm infant who is expected not to receive any fresh breast milk for 4 weeks following treatment initiation.
- •7. Informed consent is obtained from the patient’s legally acceptable representative. Every effort will be made to ensure informed consent is obtained from both parents. Where this is not possible, the local regulations will be followed in the definition of legally acceptable representative.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 432
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Expected stay at the hospital is less than 4 weeks from the first dose of study drug.
- •2. Currently receiving mechanical ventilation via endotracheal tube (continuous positive airway pressure [CPAP] or high-flow nasal cannula are not criteria for exclusion).
- •3. Require =30% oxygen (if on CPAP or in head box) or >0.5 L/min oxygen.
- •4. Evidence of severe brain disease or damage, including grade III or IV peri- or intraventricular hemorrhage, meningitis or hydrocephalus, grade III or IV intracranial hemorrhage, or periventricular leukomalacia.
- •5. Presence of major dysmorphology or congenital abnormalities that are likely to affect growth and/or development.
- •6. Current clinical evidence of hemodynamically significant persistent ductus arteriosus.
- •7. Clinical evidence of sepsis (including low or high white blood cell count and/or low platelet count and bacteriologically proven evidence of systemic infection). This should be based on the investigator’s opinion and available local laboratory reference ranges. Patients should not have received antibiotics in preceding 48 hours except where these are being administered for prophylaxis as per routine unit protocols (eg, antifungal prophylaxis with fluconazole).
- •8. Evidence of congenital infection (eg, cytomegalovirus).
- •9. Previous or current diagnosis of necrotizing enterocolitis (Bell’s stage 2 or greater).
- •10. Prior or concomitant treatment with corticosteroids, except hydrocortisone.
- •11. Presence of any condition that in the opinion of the investigator makes the patient unsuitable for inclusion.
- •12. Enrolled in another concurrent clinical intervention study.
研究者
相似试验
进行中（未招募）
不适用
A phase 3 clinical study investigating the effects of rhBSSL (an enzyme to help digestion of fat) added to pasteurized breast milk or formula in babies born prematurely.EUCTR2010-023909-35-SESwedish Orphan Biovitrum AB (publ)432
进行中（未招募）
不适用
A phase 3 clinical study investigating the effects of rhBSSL (an enzyme to help digestion of fat) added to pasteurized breast milk or formula in babies born prematurely.Prevention of growth retardation due to lack of bile salt-stimulated lipase in enteral nutritionMedDRA version: 14.1Level: PTClassification code 10036590Term: Premature babySystem Organ Class: 10036585 - Pregnancy, puerperium and perinatal conditionsEUCTR2010-023909-35-HUSwedish Orphan Biovitrum AB (publ)432
进行中（未招募）
不适用
A phase 3 clinical study investigating the effects of rhBSSL (an enzyme to help digestion of fat) added to pasteurized breast milk or formula in babies born prematurely.EUCTR2010-023909-35-DESwedish Orphan Biovitrum AB (publ)432
进行中（未招募）
不适用
A phase 3 clinical study investigating the effects of rhBSSL (an enzyme to help digestion of fat) added to pasteurized breast milk or formula in babies born prematurely.Prevention of growth retardation due to lack of bile salt-stimulated lipase in enteral nutritionMedDRA version: 14.0Level: PTClassification code 10036590Term: Premature babySystem Organ Class: 10036585 - Pregnancy, puerperium and perinatal conditionsEUCTR2010-023909-35-ESSwedish Orphan Biovitrum AB (publ)432
进行中（未招募）
1 期
A phase 3 clinical study investigating the effects of rhBSSL (an enzyme to help digestion of fat) added to pasteurized breast milk or formula in babies born prematurely.EUCTR2010-023909-35-BESwedish Orphan Biovitrum AB (publ)432